bioRxiv · 10.1101/223248
Circulating selenium and prostate cancer risk: a Mendelian randomization analysis
Abstract
In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 g/L increase in circulating selenium) did not lower overall prostate cancer risk, but increased risk of high-grade prostate cancer and type 2 diabetes. Mendelian randomization analysis uses genetic variants to proxy modifiable risk factors and can strengthen causal inference in observational studies. We constructed a genetic risk score comprising eleven single-nucleotide polymorphisms robustly (P<5x10-8) associated with circulating selenium in genome-wide association studies. In a Mendelian randomization analysis of 72,729 men in the PRACTICAL Consortium (44,825 cases, 27,904 controls), 114 g/L higher genetically-elevated circulating selenium was not associated with prostate cancer (OR: 1.01; 95% CI: 0.89-1.13). Concordant with findings from SELECT, selenium was weakly associated with advanced (including high-grade) prostate cancer (OR: 1.21; 95% CI: 0.98-1.49) and type 2 diabetes (OR: 1.18; 95% CI: 0.97-1.43; in a type 2 diabetes GWAS meta-analysis with up to 49,266 cases, 249,906 controls). Mendelian randomization mirrored the outcome of selenium supplementation in SELECT and may offer an approach for the prioritization of interventions for follow-up in large-scale randomized controlled trials.
Source connections
Explore related subjects
Keep this discovery
Yarmolinsky, J., Bonilla, C., Haycock, P. C., Langdon, R. J., Lotta, L. A., Langenberg, C., Relton, C. L., Lewis, S. J., Evans, D. M., the PRACTICAL consortium,, Smith, G. D., Martin, R. M.. 2017-11-21. Circulating selenium and prostate cancer risk: a Mendelian randomization analysis. https://doi.org/10.1101/223248
Cite the original work for its findings. Save a collection to share your selection of sources.